- Not Fee assured
- Awaiting verification
- Open Referral network
Professor Nicholas van As was appointed Medical Director of The Royal Marsden NHS Foundation Trust in January 2016. He has been a Consultant Clinical Oncologist in the Urology Unit at The Royal Marsden since 2008 and is the hospitalâ€™s Clinical Lead for stereotactic body radiotherapy (SBRT) and CyberKnife. He is also a Professor of The Institute of Cancer Research and a trustee for The Royal Marsden Cancer Charity.
He treats all stages of prostate cancer from early disease to advanced metastatic disease.
Professor van As was previously Chair of the UK SBRT Consortium and is the national clinical lead for NHS Englandâ€™s Commissioning through Evaluation Programme for SBRT. His main research interests are in stereotactic and image-guided radiotherapy, risk prediction in early prostate cancer, and functional MRI, and he has published numerous papers on these subjects and delivered presentations at international meetings. He is the Chief Investigator for the PACE trial â€“ an international, randomised controlled trial comparing SBRT to image-guided radiotherapy (IGRT) and surgery for treating prostate cancer.
Areas of interest
Urological oncology; Radiotherapy; SBRT; SABR; Cyberknife; Systemic therapy for prostate cacner
Current NHS consultant posts held
Medical director of the Royal Marsden Hopistal
Professor of Clinical Oncology at the Institute of Cancer research
Consultant Clinical Oncologist: Royal Marsden Hospital
National Clinical lead for NHS England SABR CtE programme
He has research interests in stereotactic and image-guided radiotherapy, risk prediction in early prostate cancer, and functional MRI. He is the chief investigator on the PACE trial. This is the largest international trial looking at stereotactic radiotherapy for prostate cancer
Cycling, golf, travel
Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for
prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-
label, phase 3, non-inferiority trial.
Douglas H Brand, Alison C Tree,...Emma Hall, Nicholas van As,
The Lancet Oncology. 2019;20(11):1531-154
Stereotactic ablative body radiotherapy in patients with oligometastatic cancers: a prospective, registry-based, single-arm, observational, evaluation study
Anastasia Chalkidou,â€¦Maria A Hawkins, Nick Slevin, Nicholas van As
Predicting the probability of deferred radical treatment for localised prostate cancer managed by active surveillance.
van As NJ, Norman AR, Thomas K, Khoo VS, Thompson A, Huddart RA, Horwich A, Dearnaley DP, Parker CC.
Eur Urol. 2008 Dec;54(6):1297-305.
A study of diffusion-weighted magnetic resonance imaging in men with untreated localised prostate cancer on active surveillance.
van As NJ, de Souza NM, Riches SF, Morgan VA, Sohaib SA, Dearnaley DP, Parker CC.
Eur Urol. 2009 Dec;56(6):981-7.
Prostate Stereotactic Body Radiotherapy - First UK Experience.
Tree AC, Ostler P, Hoskin P, Dankulchai P, Nariyangadu P, Hughes RJ, Wells E, Taylor H, Khoo VS, van As NJ.
Clin Oncol (R Coll Radiol). 2014 Dec;26(12):757-61.
Stereotactic body radiotherapy for oligometastases.
Tree AC, Khoo VS, Eeles RA, Ahmed M, Dearnaley DP, Hawkins MA, Huddart RA,
Nutting CM, Ostler PJ, van As NJ.
Lancet Oncol. 2013 Jan;14(1):e28-37.
Initial UK Experience of Stereotactic Body Radiotherapy for Extracranial Oligometastases: Can We Change the Therapeutic Paradigm?
K Aitken, A Tree, K Thomas, C Nutting, M Hawkins, D Tait, H Mandeville, M Ahmed, S Lalondrelle, A Miah, A Taylor, G Ross, V Khoo, N van As
Clinical Oncology 27(2015) 411-419
Metastasis-directed Therapy in Treating Nodal Oligorecurrent Prostate Cancer: A Multi-institutional Analysis Comparing the Outcome and Toxicity of Stereotactic Body Radiotherapy and Elective Nodal Radiotherapy
Elise De Bleser.. Nicholas Van As, â€¦Piet Ost
European Urology 2019 76 (6), 732-739
Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial
D Petrylak, N Vogelzang, N Budnik, P Wiechno, C Sternberg, N Van As, N Houede, D Barton ,A Fandi, U Jungnelius U, Li Shaoyi, de Wit Ronald, K Fizazi
Lancet Oncology 16 (April 2015), p417â€“425
- MBBCh University of Witwatersrand, Johannesburg 1995
- MRCP Royal College Physicians 2000
- MD(res) University of London 2013
- FRCR Royal College Radilogists 2004
Reference number 4295826
Professional bodies (positions held - last 3 yrs)
- Chair UK SABR UK SABR consortium 2019
Information for healthcare professionals (Bupa patients only, last 12 months)
Clinical supervision and planning for the delivery of chemotherapy and/or systemic anti-cancer therapy for 1-28 days - (>50)
The Royal Marsden Hospital (5-50)
Follow-up out-patient consultation - remote - (5-50)
Clinical supervision and planning for the delivery of chemotherapy and/or systemic anti-cancer therapy for 1-21 days - (5-50)
Clinical supervision of the planning of stereotactic radiosurgery e.g. SRT/SBRT and Gamma Knife - (1-5)
Clinical supervision of external beam radiotherapy, for 16 or up to and including 30 fractions - (1-5)
- Show All (7 )...